The study period extends from January 1, 2008, through December 31, 2012. ALK indicates anaplastic lymphoma kinase; ALL, acute lymphoblastic leukemia; BCC, basal cell carcinoma; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CTCL, cutaneous T-cell lymphoma; DFS, disease-free survival; ERBB2 (formerly HER2 or HER2/neu), erb-b2 receptor tyrosine kinase 2; GIST, gastrointestinal stromal tumor; NET, neuroendocrine tumor; NHL, non-Hodgkin lymphoma; NSCLC, non–small cell lung cancer; PFS, progression-free survival; Ph, Philadelphia chromosome; RCC, renal cell carcinoma; and RR, response rate.
Exact numbers of approvals depicted in this graph are given in the Results section.
Kim C, Prasad V. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall SurvivalAn Analysis of 5 Years of US Food and Drug Administration Approvals. JAMA Intern Med. 2015;175(12):1992-1994. doi:10.1001/jamainternmed.2015.5868
Most contemporary approvals of new cancer drugs are made on the basis of a surrogate end point, such as response rate or progression-free survival (PFS).1 When the approval is based on a surrogate end point, subsequent studies are advised and often obligated to clarify the drug’s effect on overall survival. One such drug is bevacizumab, which received accelerated approval on the basis of PFS for patients with metastatic breast cancer. Later findings revealed no improvement in overall survival and significant toxicity, which required a removal of marketing authorization.2
A 2009 Government Accountability Office report criticized the US Food and Drug Administration (FDA) for failing to enforce postmarketing study commitments for surrogate approvals. Among the more than 400 postmarketing studies requested, approximately 30% were pending, ongoing, delayed, or terminated years later, yet the FDA never exercised its authority to remove a product from the market.3 For these reasons, we sought to investigate how often cancer drugs are approved based on a surrogate end point, whether subsequent studies for these drugs are reported, and whether the drugs improve overall survival.
We examined all marketing approvals by the FDA from January 1, 2008, through December 31, 2012. We identified the pathway for approval (accelerated vs traditional) and the surrogate end point used, such as tumor response rate or PFS. This investigation of published reports was exempt from institutional review board approval.
For all drugs approved on the basis of a surrogate end point, we performed a systematic search of the published literature using Google Scholar as of August 22, 2015, and identified any subsequent reports of the drug’s effect on overall survival. We credited a drug for improving overall survival if that drug improved survival as the sole investigational agent in any combination or in any line of treatment (eg, if approved for second-line treatment of metastatic disease, but the drug improved survival in first-line treatment, we would credit the drug as improving survival). We identified whether crossover (from the control arm to the investigational agent) was used in the randomized clinical trial or via a postprotocol expansion study. We analyzed the study data from August 22 to September 1, 2015.
We identified 54 approvals made during our search period, with 36 drugs (67%) approved on the basis of a surrogate end point. Figure 1 shows all surrogate approvals, the efficacy end point at the time of approval, and the regulatory pathway. Approval was granted on the basis of a surrogate for all 15 accelerated approvals (100%) and 21 of 39 traditional approvals (54%). Rate of response, measured by a reduction in tumor size or volume, was the primary measure of efficacy for 19 of 36 surrogate-based approvals (53%), whereas PFS or disease-free survival was cited as the basis of 17 of 36 approvals (47%).
With a median follow-up of 4.4 years, 5 drugs were subsequently shown to improve overall survival in randomized studies (in 1 of 15 accelerated approvals and in 4 of 21 traditional approvals), 18 drugs failed to improve overall survival (in 6 of 15 accelerated approvals and in 12 of 21 traditional approvals) as primary or secondary outcomes, and 13 drugs continue to have unknown survival effects, meaning they remain untested or they have no reported survival results as primary or secondary outcome (in 8 of 15 accelerated approvals and in 5 of 21 traditional approvals). Figure 2 compares the percentage of approved drugs with known and unknown effects on overall survival based on our systematic review of subsequent literature. The use of crossover occurred in 11 of 36 trials (31%) and did not differ among trials that found a survival advantage vs those that did not (1 of 5 [20%] vs 10 of 18 [55%]; P = .16).
During our study period, 36 of 54 contemporary cancer drug approvals (67%) were made on the basis of a surrogate end point. With several years of follow-up, 31 (86%) of these approvals (57% of the 54 drugs approved) have unknown effects on overall survival or fail to show gains in survival. Our results show that most cancer drug approvals have not been shown to, or do not, improve clinically relevant end points.
Since 2008, the FDA has approved a higher percentage of drugs than previously,4 and cancer drugs are approved on the basis of surrogates that have poor correlations with overall survival.2 Our results suggest that the FDA may be approving many costly, toxic drugs that do not improve overall survival. Enforcement of postmarketing studies is therefore of critical importance.
Corresponding Author: Vinay Prasad, MD, MPH, Division of Hematology and Medical Oncology, Knight Cancer Center, Oregon Health and Sciences University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239 (email@example.com).
Published Online: October 19, 2015. doi:10.1001/jamainternmed.2015.5868.
Author Contributions: Drs Kim and Prasad had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Both authors.
Acquisition, analysis, or interpretation of data: Both authors.
Drafting of the manuscript: Prasad.
Critical revision of the manuscript for important intellectual content: Kim.
Statistical analysis: Kim.
Study supervision: Prasad.
Conflict of Interest Disclosures: None reported.